The combined inhibition of BTK (“on-target” effect) and other kinases (“off-target” effect) can have additive or synergistic anti-tumor effects but also induce undesired side effects, such as atrial fibrillation (AF) and bleeding. The gene discussed is BTK; the disease is atrial fibrillation.